Www-.guardanthealth.com

Guardant Health Presents New Data Showing Blood Test Accuracy …

WEBGuardant Health, Inc. today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC).

Actived: 6 days ago

URL: https://www-.guardanthealth.com/2022/05/21/guardant-health-presents-new-data-showing-blood-test-accuracy-in-detecting-colorectal-cancer-in-first-of-its-kind-prospective-study-at-digestive-disease-week-2022/

Craig Eagle of Guardant Health: In Light Of The Pandemic, Here …

WEBPlace greater focus on healthcare equity — COVID-19 was a reminder of how disease disproportionately impacts certain groups, including people of color and lower socioeconomic status. Unfortunately, cancer, which remains a leading killer of Americans, is no different. We must continue to promote more equitable access to healthcare and the …

Category:  Cancer Go Health

Guardant Health to showcase new data at ESMO 2022 …

WEBPresentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers

Category:  Cancer Go Health

Guardant Health Announces Partnership with Epic to Streamline …

WEBA partnership with Epic, the nation’s most widely used comprehensive health record, to integrate the company’s broad portfolio of cancer tests with Epic.

Category:  Cancer Go Health

Early-stage Cancer Studies

WEBOur Approach. Our Commitment; For Patients; For Healthcare Providers; For Biopharma Partners; For Employers; Products. Tests for Cancer Screening; Tests for Patients with Early-stage Cancer

Category:  Cancer Go Health

Guardant Health Receives Medicare Coverage for Guardant …

WEBFirst blood-only liquid biopsy test for molecular residual disease testing now covered for certain fee-for-service Medicare patients in US with stage II or III colorectal cancer

Category:  Cancer Go Health

Guardant360® CDx liquid biopsy is helping to bring the …

WEBGuardant360® CDx liquid biopsy is helping to bring the promise of precision oncology to more advanced cancer patients Comprehensive genomic profiling (CGP), also known as biomarker testing, genotyping, or tumor profiling, is a test

Category:  Cancer Go Health

Fight Colorectal Cancer and Guardant Health Join Forces to …

WEBCookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".

Category:  Health Go Health

Clinical Validation of a Cell-free DNA Blood-based Test for …

WEB@DDWMEETING | #DDW2023 Background • Despite the widespread availability of many CRC screening options, there arepersistentbarriers andscreening rates remain suboptimal1 • Approximately 59% of eligible individuals aged 45 years+ are adherent 2, well below the target of 80%3 • Ablood-based CRC screening test, completed as part of a routine …

Category:  Health Go Health

Guardant Health and The Royal Marsden NHS Foundation Trust …

WEBIncreased accessibility to Guardant Health’s liquid biopsy testing will enable clinicians to personalize treatments more accurately for patients with late-stage cancer

Category:  Cancer Go Health

Guardant Health to Report Fourth Quarter and Full Year 2022 …

WEBGuardant Health will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at …

Category:  Health Go Health

Guardant Health Announces Additions to Leadership Team

WEBAt Guardant, we have built one of the most transformative platforms in diagnostics and we think extensively about how we get work done more efficiently, from development through delivery, to fulfill our primary mission of helping patients

Category:  Health Go Health

Guardant Health and Blueprint Medicines present real-world data

WEBAnalysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib treatment

Category:  Health Go Health

6603 BRCA1 promoter methylation in sporadic breast cancer …

WEBBRCA1promoter methylation in sporadic breast cancer patients detected by liquid biopsy Jennifer Yen1, Sai Chen1, Colby Jenkins1, LeylahM.Drusbosky1, Brooke Overstreet1, Jun Zhao1, Yu Fu1, TingtingJiang1, ShileZhang1, Stephen Pettitt2, Andrew Tutt2,3, Michael Dorschner1, Lauren Lawrence1, Han-Yu Chuang1 1Guardant Health, Inc. Redwood …

Category:  Cancer Go Health

November 1, 2022 The Office of Management and Budget …

WEBreviews each year.”2 Furthermore, in response to a Congressional inquiry, the Director of AHRQ indicated that the USPSTF could complete more reviews and modify its processes to be more nimble and better adapt to medical advancements if the funding level for its …

Category:  Medical Go Health

Why This Message Motivates for Colorectal Cancer Screening

WEBIn the book Switch: How to Change Things When Change is Hard by the Heath brothers, the authors share a story about the St. Lucia Parrot that only exists on the island of St. Lucia.

Category:  Health Go Health